Candida auris can be deadly, particularly for people who are already seriously ill. The estimated crude mortality rate for hospitalized patients with C. auris is 34%, and that figure climbs to 47% when the fungus enters the bloodstream. However, most people who die with a C. auris infection had severe underlying health conditions, making it difficult to determine exactly how much the fungus itself contributed to death versus their other illnesses.
How Dangerous C. auris Actually Is
C. auris is not a threat to healthy people walking around in everyday life. It primarily strikes patients who are already in healthcare facilities with serious medical problems and who rely on devices like breathing tubes, feeding tubes, IV catheters, or urinary catheters. These devices create direct pathways for the fungus to enter the body.
Once inside, C. auris can cause invasive infections in the bloodstream or abdominal cavity. Among hospitalized patients in the U.S. between 2017 and 2022, 21% died in the hospital and another 13% were discharged to hospice care. The combined crude mortality rate of 34% is high, but context matters: these patients were already among the sickest people in the healthcare system. Bloodstream infections carry the worst prognosis, with nearly half of those patients dying.
Why Drug Resistance Makes It Worse
What sets C. auris apart from other fungal infections is how resistant it is to the medications normally used to treat them. Out of more than 8,000 samples tested in the U.S. during 2022 and 2023, 95% were resistant to the most commonly prescribed antifungal, fluconazole. About 15% resisted a second major antifungal class, and that number nearly doubled from 10% in 2022 to 19% in 2023. A small fraction, less than 1%, were resistant to every available antifungal drug.
This resistance profile is what makes C. auris so concerning from a public health standpoint. When a patient develops a serious fungal infection and the standard first-line treatments don’t work, doctors have very few backup options. The CDC classifies C. auris as an urgent threat for exactly this reason.
How It Spreads in Healthcare Settings
C. auris spreads easily between patients in hospitals and long-term care facilities. The fungus can colonize a patient’s skin without causing symptoms, and it sheds onto surrounding surfaces. It has been cultured from bedside tables, bedrails, and even windowsills far from the patient. Unlike many microorganisms, it can survive on surfaces for months.
Standard hospital cleaning doesn’t always eliminate it. Common disinfectants, including those based on quaternary ammonium compounds, are ineffective against C. auris. Healthcare facilities need specialized EPA-registered products to kill it. This persistence on surfaces, combined with the difficulty of eradicating it, helps explain why case counts keep climbing. The U.S. reported 6,304 new clinical cases in 2024, though the rate of increase has slowed since 2022.
It’s Hard to Identify Correctly
One of the more troubling aspects of C. auris is that standard laboratory tests frequently misidentify it as other, less dangerous fungi. Depending on the testing method used, it can be confused with at least a dozen different yeast species. This means patients may not receive the right treatment immediately, and infection control measures may not be triggered when they should be. Specialized testing, such as molecular sequencing, is needed for accurate identification.
Who Is Most at Risk
Your risk of a C. auris infection is essentially zero if you’re healthy and not spending time in healthcare facilities. The people most vulnerable share a common profile: severe underlying medical conditions, extended hospital or nursing facility stays, and reliance on invasive medical devices. Think ICU patients on ventilators, people receiving long-term IV medications, or residents of long-term acute care facilities.
Among the hospitalized patients studied between 2017 and 2022, those who survived were often discharged to skilled nursing facilities (28%) or long-term acute care centers (15%), suggesting that many remained seriously ill even after recovering from the infection itself.
How C. auris Infections Are Treated
The recommended first-line treatment is a class of antifungal drugs called echinocandins, given intravenously. These remain effective against the vast majority of C. auris strains, with only about 1% showing resistance so far. If echinocandins aren’t working after five days, or if lab testing shows resistance, doctors typically switch to a different IV antifungal.
Treatment is entirely hospital-based and delivered through an IV, which underscores the severity of these infections. There is no oral medication you’d pick up at a pharmacy. The challenge grows significantly for patients infected with strains resistant to multiple drug classes, because the remaining options are limited and can carry serious side effects. The small but real possibility of panresistant infections, where no available drug works, is the nightmare scenario that public health officials are working to prevent.